Is to be held in Kaluga on April 4, 2017. The event is to be attended by key pharmaceutical market players, including top officials from federal government agencies, representatives regional government institutions; top managers from pharmaceutical companies, R&D centers, innovative business incubators, distributors and insurance companies, pharmacy retail chains, trade associations, as well as lead analysts, investors, and experts.
The future of pharmaceutical industry is to be discussed at a forum organized by the Vedomosti in cooperation with the Government of Kaluga Region and the Agency for Innovative Development – Kaluga Region Cluster Development Center and supported by Kaluga Pharmaceutical Cluster.
The discussion will be focused on the following subjects: pharmaceutical industry development analytical research and forecasts, industry localization and development of pharmaceutical clusters, new Russian pharmaceutical industry (the future of Russian developments), new technologies in pharmaceutical industry and healthcare digitalization, market pricing.
According to analytical companies’ forecasts, the global pharmaceutical market is to grow in 2017. Pharmaceutical business in Russia grows as well. Sales in 2017 grew by 20 at average. The pharmaceutical market structure has changed following a number of government resolutions governing the industry. As of September 2016 the industry changed drastically as compared to September 2015: The share of medicines with the average price per pack increased while the share of expensive medicines decreased on the backdrop of average price growth. According to a research results, the share of Russian-made medicines in the local market was slightly above 50% in September 2016.
Kaluga Pharmaceutical Cluster in Brief:
Pharmaceutical industry production facilities located in Kaluga Region manufacture about 139 products. A few dozens more are to be added in the near future. Finished pharmaceutical products account for over 89% of the total cluster output.
In October 2016 Kaluga Pharmaceutical Cluster became a member of Development of Innovative Clusters, Global Leaders in the Field of Investment Attractiveness, a top priority project of the Ministry for Economic Development of the Russian Federation.
Pharmaceutical Industry, Bio Technology and Bio Medicine Kaluga Region Cluster was established in 2011. In 2012 it received a legal status of a non-for-profit partnership (Kaluga Pharmaceutical Cluster non-for-profit partnership).
Kaluga pharmaceutical cluster areas of specialization: preclinical and clinical studies, development, synthesis and introduction of pharmaceutical substances and radiology medicine products, production of finished pharmaceutical products, pharmaceutical substances, infusion solutions and parenteral nutrition products.
Kaluga Pharmaceutical Cluster includes major global and Russian pharmaceutical companies, including Hemopharm, AstraZeneca, Niarmedic Pharma, Novo Nordisk, STADA CIS, Berlin Chemie/Menarini), innovative SMEs, leading R&D and education centers – over 60 participants in total.
Kaluga Pharmaceutical Cluster strategic objective is to become a Top3 Russian pharmaceutical cluster in terms of market share. According to the existing forecast, Kaluga pharmaceutical cluster’s market share is to reach 10-12% by 2020.
According to an appraisal of 750 clusters carried out by the European Secretariat for Cluster Analysis (ESCA) in 2015 only five Russian clusters received Bronze Cluster Excellence certificates, including Kaluga pharmaceutical cluster, which has the highest rating in Health and Medical Science category. The performance was compared to 19 leading relevant European clusters.
Early in November 2016 a cooperation agreement was signed between Kaluga Pharmaceutical Cluster and C.H.I.C.O. (Cluster of Health, Innovation and Community), one of the leading Italian clusters. The document was signed at Meet in Italy for Life Sciences partnering forum. Two clusters are to cooperate in a number of top priority areas. They are to share best practices, take part in joint projects, develop new processes and manufacture original pharmaceutical substances.